Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Nineteen European Union countries, including France and Germany, are calling for the European Investment Bank to boost lending for the defence industry as the 27-nation EU seeks ways to improve its ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

“I think we all thought that this was a way to maybe try to force a sale, and also a way to try ... Pfizer doesn’t have the balance sheet capacity after Seagen, and its CDK4 program represents ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Product sales rose 11%, led by 14% volume growth. Products including Repatha, Blincyto and Tezspire all posted at least double digit sales growth, the company said. For the current year, Amgen expects ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable ...

The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks. Thousand Oaks, CA-based Amgen is one of the ...